AIDS-related Burkitt's-type lymphomas are a target for lymphokine-activated killers induced by interleukin-2 and prolactin (44051)

Experimental Biology and Medicine

Volumn 213, Issue 2, 1996, Pages 196-205

  Gaidano, Gianluca ^b   Contarini, Maria ^b   Pastore, Cristina ^b   Saglio, Giuseppe ^b   Matera, Lina ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2; PROLACTIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; BURKITT LYMPHOMA; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXICITY; HUMAN; HUMAN CELL; LYMPHOKINE ACTIVATED KILLER CELL;

BURKITT LYMPHOMA; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; INTERLEUKIN-2; KILLER CELLS; KILLER CELLS, LYMPHOKINE-ACTIVATED; LYMPHOMA, AIDS-RELATED; PROLACTIN; RECOMBINANT PROTEINS; TUMOR CELLS, CULTURED;

EID: 0029955498     PISSN: 00379727     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Beral V, Peterman T, Berkelman R, Jaffe H. AIDS-associated non-Hodgkin lymphoma. Lancet 337:805-809, 1991.
2. Karp J, Broder S. Acquired immunodeficiency syndrome and non-Hodgkin's lymphomas. Cancer Res 51:4743-4756, 1991.
3. Levine AM. Acquired immunodeficiency syndrome-related lymphoma. Blood 80:8-20, 1992.
4. Knowles DM, Chadburn A. Lymphadenopathy and the lymphoid neoplasms associated with the acquired immune deficiency syndrome (AIDS). In: Knowles DM, Ed. Neoplastic Hematopathology. Baltimore: Williams & Wilkins, pp773-835, 1992.
5. Magrath IT, Jain V, Jaffe ES. Small non cleaved cell lymphoma. In: Knowles DM, Ed. Neoplastic Hematopathology. Baltimore: Williams & Wilkins, pp749-772, 1992.
6. Gaidano G, Carbone A. AIDS-related lymphomas: From pathogenesis to pathology. Br J Haematol 90:235-243, 1995.
7. Gaidano G, Dalla-Favera R. Molecular pathogenesis of AIDS-related lymphomas. Adv Cancer Res 67:113-153, 1995.
8. Ballerini P, Gaidano G, Gong JZ, Tassi V, Saglio G, Knowles DM, Dalla-Favera R. Multiple genetic lesions in acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma. Blood 81:166-176, 1993.
9. Ortaldo JR. Mason A, Overton R. Lymphokine-activated killer cells. Analysis of progenitors and effectors. J Exp Med 164:1193-1205, 1986.
10. Phillips H, Takeshita T, Sugamura K, Lanier LL. Activation of natural killer cells via the p75 interleukin-2 receptor. J Exp Med 170:291-296, 1989.
11. Robertson MJ, Ritz J. Biology and clinical relevance of natural killer cells. Blood 76:2421-2438, 1991.
12. Trinchieri G. Biology of natural killer cells. Adv Immunol 47:187-376, 1989.
13. Vanhaesebroeck B, Grooten J, Fiers W. An ongoing in vivo immune response affects the abundancy and differentiation of lymphokine-activated killer cell precursors, but does not influence their broad spectrum target reactivity. J Immunol 143: 1396-1402, 1989.
14. Cesano A, Oberholtzer E, Contarini M, Geuna M, Bellone G, Matera L. Independent and synergistic effect of interleukin-2 and prolactin on development of T- and NK-derived LAK effectors. Immunopharmacology 28:67-75, 1994.
15. Brenner BG, Dascal A, Margolese RG, Wainberg MA. Natural killer function in patients with acquired immunodeficiency syndrome and related diseases. J Leucocyte Biol 46:75-83, 1989.
16. Brenner BG, Gryllis C, Gornitsky M, Wainberg MA. Changes in natural immunity during the course of HIV-1 infection. Clin Exp Immunol 93:142-148, 1993.
17. Cauda R, Goletti D, Lucia MB, Tumbarello M, Rumi C, Orengo AM, Moretta A. Analysis of Natural Killer (NK) cell subsets defined by the expression of two novel surface antigens (EB6 and GL183) in AIDS and AIDS-related conditions. Clin Immunol Immunopathol 70:198-205, 1994.
18. Landay A, Ohlsson-Wilhelm B, Giorgi JV. Application of flow cytometry to the study of HIV function. AIDS 4:479-497, 1990.
19. Sirianni MC, Soddus S, Malorni W, Arancia G, Aiuti F. Mechanism of defective natural killer cell activity in patients with AIDS is associated with defective distribution of tubulin. J Immunol 140:2565-2568, 1988.
20. + lymphocytes during HIV infection. AIDS Res Hum Retroviruses 4:121-129, 1988.
21. Chin TW, Plaeger-Marshall S, Haas A, Ank BJ, Stiehm ER. Lymphokine-activated killer cells in primary immunodeficiencies and acquired immunodeficiency syndrome. Clin Immunol Immunopathol 53:449-459, 1989.
22. + individuals. Clin Exp Immunol 89:356-361, 1992.
23. Benjamin D, Knobloch TJ, Dayton MA. Human B-cell interleukin-10: B-cell lines derived from patients with acquired immunodeficiency syndrome and Burkitt's lymphoma constitutively secrete large quantities of interleukin-10. Blood 80:1289-1298, 1992.
24. Gaidano G, Parsa NZ, Tassi V, Della-Latta P, Chaganti RSK, Knowles DM, Dalla-Favera R. In vitro establishment of AIDS-related lymphoma cell lines: Phenotypic characterization, oncogene and tumor suppressor gene lesions, and heterogeneity in Epstein-Barr virus infection. Leukemia 7:1621-1629, 1993.
25. Ganser A, Carlo-Stella C, Bartram CR, Boehm Th, Heil G, Henglein B, Müller H, Raghavachar An, von Briesen H, Griesinger F, Völkers B, Ruebsamen-Waigmann H, Helm EB, Hoelzer D. Establishment of two Epstein-Barr virus negative Burkitt cell lines from a patient with AIDS and B-cell lymphoma. Blood 72:1255-1260, 1988.
26. Magrath IT, Erikson J, Whang-Peng J, Sieverts H, Armstrong G. Benjamin D, Triche T, Alabaster O, Croce CM. Synthesis of kappa light chains by cell lines containing an 8;22 chromosomal translocation derived from a male homosexual with Burkitt's lymphoma. Science 222:1094-1098, 1983.
27. Roncella S, Francia di Celle P, Cutrona G, Carbone A, Sessarego M, Landonio G, Foà R, Rowe M, Ferrarini M. Cytogenetic rearrangement of C-MYC oncogene occurs prior to infection with Epstein-Barr virus in the monoclonal malignant B cells from an AIDS patient. Leuk Lymphoma 9:157-164, 1993.
28. Gaidano G, Ballerini P, Gong JZ, Inghirami G, Neri A, Newcomb EW, Magrath IT, Knowles DM, Dalla-Favera R. p53 mutations in human lymphoid malignancies: Association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci USA 88:5413-5417, 1991.
29. Kiwanuka J, Shiramizu B, Sandlund T, Barriga F, McManaway M, Novikovs L, Huber B, Magrath IT. The contribution of Burkitt's lymphoma cell lines to the understanding of the pathogenesis of Burkitt's lymphoma. Cancer Rev 10:63-91, 1988.
30. Pross HF, Baines MG, Rubin P, Shragge P, Petterson MS. Spontaneous human lymphocyte-mediated cytotoxicity against tumor target cells. IX. The quantitation of natural killer cells activity. J Clin Immunol 1:51-64, 1981.
31. Dye JF, Somres SS, Guillou PJ. Simplified quantitation of cytotoxicity by integration of specific lysis against effector cell concentration at a constant target cell concentration and measuring the area under the curve. J Immunol Methods 138:1-13, 1991.
32. Matera L, Cesano A, Muccioli G, Veglia F. Modulatory effect of prolactin on the DNA synthesis rate and NK activity of large granular lymphocytes. Int J Neurosci 51:265-267, 1990.
33. Carbona A, Gloghini A, Gaidano G, Cilia AM, Bassi P, Polito P, Vaccher E, Saglio G, Tirelli U. AIDS-related Burkitt's lymphoma: Morphologic and immunophenotypic study of biopsy specimens. Am J Clin Pathol 103:561-567, 1995.
34. Carbona A, Tirelli U, Gloghini A, Volpe R, Boiocchi M. Human immunodeficiency virus-associated systemic lymphomas may be subdivided into two main groups according to Epstein-Barr viral latent gene expression. J Clin Oncol 11:1674-1681, 1993.
35. Hui PK, Feller AC, Lennert K. High grade non-Hodgkin's lymphoma of B-cell type. 1. Histopathology. Histopathology 12: 127-143, 1988.
36. Raphael M, Gentilhomme O, Tulliez M, Byron P-A, Diebold J, the French Study Group of Pathology for Human Immunodeficiency Virus-Associated Tumors. Histopathologic features of high-grade non-Hodgkin's lymphomas in acquired immunodeficiency syndrome. Arch Pathol Lab Med 115:15-20, 1991.
37. Taniguchi T. Cytokine signalling through nonreceptor protein tyrosine kinases. Science 268:251-255, 1995.
38. Viselli SM, Stanek EM, Mukherjee P, Hymer WC, Mastro AM. Prolactin-induced mitogenesis of lymphocytes from ovariectomized rats. Endocrinology 129:983-990, 1991.
39. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linchan WM, Robertson CM, Lee RE, Rubin JT, Seipp CA, Simpson CG, White DE. Progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316:889-897, 1987.
40. Rosenberg SA, Lotz MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni S, Vetto JT, Seipp CA, Simpson C, Reichert CM. Observation on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313:1485-1492, 1985.
41. West WH, Tauer KW, Yannelli JR, Marshall GD, Orr DW, Thurman GB, Oldham RK. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 316:898-905, 1987.
42. Boyle MJ, Swanson CE, Turner JJ, Thompson IL, Roberts J, Penny R, Cooper DA. Definition of two distinct types of AIDS-associated non-Hodgkin's lymphoma. Br J Haematol 76:506-512, 1990.
43. Levine AM, Sullivan-Halley J, Pike MC, Rarick MU, Loureiro C, Bernstein-Singer M, Willson E, Brynes R, Parker J, Rasheed S, Gill PS. Human immunodeficiency virus-related lymphoma. Prognostic factors predictive of survival. Cancer 68:2466-2472, 1991.
44. Pluda JM, Venzon DJ, Tosato G, Lietzau J, Wyvill K, Nelson DL, Jaffe ES, Karp JE, Broder S, Yarchoan R. Parameters affecting the development of non-Hodgkin's lymphoma in patients with severe combined immunodeficiency virus infection receiving antiretroviral therapy. J Clin Oncol 11:1099-1107, 1993.